Ilaria Del Giudice | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response	LEUKEMIA & LYMPHOMA	2022
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab	HAEMATOLOGICA	2021
TH2/TH1 shift under Ibrutinib treatment in chronic lymphocytic leukemia	FRONTIERS IN ONCOLOGY	2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases	AMERICAN JOURNAL OF HEMATOLOGY	2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	AMERICAN JOURNAL OF HEMATOLOGY	2021
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	AMERICAN JOURNAL OF HEMATOLOGY	2021
High basal maximal standardized uptake value (Suvmax) in follicular lymphoma identifies patients with a low risk of long-term relapse	CANCERS	2021
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study	BLOOD	2021
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial	CANCERS	2021
Does MRD have a role in the management of iNHL ?	HEMATOLOGY	2021
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study	JOURNAL OF CLINICAL ONCOLOGY	2021
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases	EUROPEAN JOURNAL OF HAEMATOLOGY	2021
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study	LEUKEMIA	2020
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations	BRITISH JOURNAL OF HAEMATOLOGY	2020
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia	HAEMATOLOGICA	2020
Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript	LEUKEMIA & LYMPHOMA	2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma	HEMATOLOGICAL ONCOLOGY	2020
COMPLEX KARYOTYPE IS ASSOCIATED WITH A LESS FAVORABLE OUTCOME AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114).	HemaSphere 2020; 4 (S1) p 290	2020
COMPLEX KARYOTYPE AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114)	Haematologica, 2020; 105(s2):s28	2020
Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia	HAEMATOLOGICA	2019

Progetti di Ricerca

Multicentric retrospective-prospective observational study on the clinical application of the molecular profile (somatic mutations of IGHV and TP53 genes) to guide the therapeutic choices in the real-life for patients affected by chronic lymphocytic...
Monitoraggio non invasivo della leucemia linfatica cronica trattata con approcci 'chemo-free' mediante next-generation sequencing/droplet digital PCR sul DNA tumorale plasmatico circolante (ctDNA).
MUTAZIONI CLONALI E SUBCLONALI DEI GENI TP53, BTK e PLCg2 NELLA LEUCEMIA LINFATICA CRONICA PRE- E POST-TERAPIA. USO DELLE TECNICHE DI NEXT-GENERATION SEQUENCING PER LO STUDIO DELL'EVOLUZIONE CLONALE DELLA MALATTIA E DEI MARCATORI ASSOCIATI ALLA REFR...